J&J says new data indicates an extra dose of its COVID-19 vaccine can boost antibody levels

Shares of Johnson & Johnson
JNJ,
-1.25%
gained 0.8% in premarket trading on Wednesday after the company shared interim clinical data that indicates Americans who have received its single-dose COVID-19 vaccine should get a second dose. J&J said in a news…

Click here to view the original article.